Functionalized MoS2-nanoparticles for transdermal drug delivery of atenolol

• Published in: Drug delivery Vol. 27; no. 1; pp. 909 - 916
• Main Authors: Zhang, Kai, Zhuang, Yanling, Zhang, Weidan, Guo, Yali, Liu, Xiaochang
• Format: Journal Article
• Language: English
• Published: Philadelphia Taylor & Francis 01.01.2020; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: biomedicine; cationic hydroxyethyl cellulose; Drug delivery systems; drug release; Molybdenum disulfide; Nanoparticles; transdermal drugs; Transdermal medication; transition-metal dichalcogenides
• ISSN: 1071-7544; 1521-0464; 1521-0464
• DOI: 10.1080/10717544.2020.1778815

Molybdenum disulfide (MoS 2 ) has excellent photothermal conversion abilities, an ultra-high specific surface area, and has been extensively explored for use in biomedicine. However, the high toxicity associated with MoS 2 has limited its biological applications for in vivo photothermal therapy and drug delivery systems. Herein, we have developed cationic hydroxyethyl cellulose (JR400) surface-modified MoS 2 nanoparticles (NPs) that are responsive to near-infrared (NIR) laser irradiation as a transdermal drug delivery system (TDDS). Herein, we confirmed the preparation of hexagonal phase MoS 2 with robust surface modification with JR400. The flower-like morphology of the NPs had an average diameter of 355 ± 69.3 nm limiting the absorption of the NPs through the stratum corneum. With the ability to efficiently load 90.4 ± 0.3% of the model drug atenolol (ATE), where 1 g of JR400-MoS 2 NPs was able to load 3.6 g ATE, we assayed the controlled release capacity in vitro skin penetration studies. These JR400-MoS 2 NPs showed further enhancement under NIR stimulation, with a 2.3-fold increase in ATE skin penetration. Furthermore, we verified in vivo that these JR400-MoS 2 NPs do not cause skin irritation suggesting that they are promising new TDDS candidates for small molecule drugs.